Risk and prognostic factors for acute GVHD based on NIH consensus criteria

SE Lee, BS Cho, JH Kim, JH Yoon, SH Shin… - Bone Marrow …, 2013 - nature.com
SE Lee, BS Cho, JH Kim, JH Yoon, SH Shin, SA Yahng, KS Eom, YJ Kim, HJ Kim, S Lee…
Bone Marrow Transplantation, 2013nature.com
To investigate the risk factors for acute GVHD (aGVHD), based on NIH consensus criteria
(NCC), we evaluated 775 patients who underwent allogeneic transplantation. Of them, 346
patients developed aGVHD by NCC, in whom we also analyzed factors affecting aGVHD-
specific survival. The cumulative incidence of aGVHD was 44.7%, consisting of classic
aGVHD (n= 320) and late-onset (n= 26). Multivariate analyses revealed that younger age
(P= 0.015), unrelated donors (P= 0.004) and acute leukemia compared with other …
Abstract
To investigate the risk factors for acute GVHD (aGVHD), based on NIH consensus criteria (NCC), we evaluated 775 patients who underwent allogeneic transplantation. Of them, 346 patients developed aGVHD by NCC, in whom we also analyzed factors affecting aGVHD-specific survival. The cumulative incidence of aGVHD was 44.7%, consisting of classic aGVHD (n= 320) and late-onset (n= 26). Multivariate analyses revealed that younger age (P= 0.015), unrelated donors (P= 0.004) and acute leukemia compared with other hematologic malignancies (P= 0.005) were significant risk factors for aGVHD, whereas PBSCs showed no association (P= 0.720). Multivariate analyses, with only aGVHD patients, revealed that late-onset aGVHD had superior aGVHD-specific survival to classic aGVHD (P= 0.044), and identified the association of visceral organ involvement (P= 0.002), severity of aGVHD at onset (P= 0.035) and advanced disease status (P< 0.001) with inferior aGVHD-specific survival. In conclusion, this study demonstrates the risk and prognostic factors for aGVHD by NCC with some differences with the previous reports that were based on old criteria. The difference in the risk factors according to different criteria will give insights about the pathophysiology of GVHD. The better prognosis of late-onset aGVHD than of classic aGVHD raises the necessity for prospective trials with a large cohort focusing on the onset time.
nature.com